Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eaxCCfbwoceUhDuNaldH

November 28, 2012
Sign upForwardArchiveAdvertiseRead more at SmartBrief.com
News for nuclear medicine and molecular imaging professionals
 
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.

  Top Story 
 
  • PET/MRI on par with PET/CT in tracking gynecological cancers
    PET/MRI performed comparably with PET/CT in maximum standardized uptake values, detection of disease location and metabolic tumor volume in patients with gynecological cancers, according to a study presented at a radiology meeting. In addition, PET/MRI allows for comparison of tumor parameters between different MR sequences and PET, said lead study author Dr. Maria Thomas of the Mallinckrodt Institute of Radiology at Washington University in St. Louis. PET/MRI's "superior soft-tissue resolution is very valuable in assessment of pelvic malignancies, and we feel this will potentially replace PET/CT for radiation treatment planning at our institution in the future," Thomas said. AuntMinnie.com (free registration) (11/27) LinkedInFacebookTwitterEmail this Story
 
  ADVERTISEMENT  
UltraSPECT's Dose-Reduction Solutions standardize protocols achieving less than 9 mSv total radiation exposure
Utilization of UltraSPECT's dose reduction software complies with Image Wisely® applying clinically proven reconstruction applications enabling the usage of all protocols with no compromise in image quality. UltraSPECT provides economical upgrade options for all NM cameras. For more information click here.

  Clinical News & Research 
  • Study: "Chemo brain" is real medical condition
    Researchers using PET/CT reported at a radiology conference that they have found physiological evidence that "chemo brain," a phenomenon resulting from chemotherapy that is characterized by memory problems and mental haziness, is a real medical condition. Researchers said they have observed reduced metabolism in brain areas that play a role in problem solving, tracking daily events, sequencing and remembering things in the long term. The scan results also showed the condition was temporary, with normal metabolism resuming in affected brain areas after some time, researchers said. FoxNews.com (11/27) LinkedInFacebookTwitterEmail this Story
  • Studies differ on tests' effect on cancer risk
    Researchers at a radiology meeting reported a rapid increase in chest and cardiac CT and nuclear medicine tests between 2000 and 2010. For a child or young adult who had at least two tests before turning 23, the 10-year risk of developing breast cancer from the tests rose, according to the study. Another study presented at the same meeting did not find an increase in cancer risk from screening mammography scatter radiation. PhysiciansBriefing.com/HealthDay News (11/27) LinkedInFacebookTwitterEmail this Story
  Industry Report 
  • GE showcases new technologies, system upgrades
    GE Healthcare is showcasing new technologies at a radiology meeting, including its Discovery PET/CT 610, a hybrid PET/CT scanner with improved sensitivity to allow for quicker scans at lower radiation doses. The system is designed for use with fluorine tracers. The company also has upgraded its Discovery NM/CT 670 SPECT system to allow for better image quality with lower radiation doses. AuntMinnie.com (free registration) (11/27) LinkedInFacebookTwitterEmail this Story
  News from the Field 
  • Prana ready to begin 12-month Alzheimer's drug study
    Prana Biotechnology has completed enrollment for its IMAGINE trial, a 12-month midstage study that will test the experimental Alzheimer's disease drug PBT2. The study will employ PiB-PET imaging to determine how PBT2 affects amyloid deposits in the brain and F-FDG-PET scans to measure whether the drug can boost brain activity. PharmaLive.com/News release (11/27) LinkedInFacebookTwitterEmail this Story
  Health Policy 
  • Agency sets comment period for stage 3 MU measures
    Comments on the CMS draft recommendations for stage 3 meaningful use objectives for the EHR incentive program may be submitted until Jan. 14, according to the Office of the National Coordinator for Health IT. Health care groups and providers may give input on objectives for meaningful use, quality metrics and privacy and security measures. BeckersHospitalReview.com (11/27) LinkedInFacebookTwitterEmail this Story
  Advancing Health Care 
  • Independent evaluations might restore faith in drug trials
    Many in the medical community and the general public have lost faith in drugmaker-sponsored research, prompting calls for greater transparency. "It’s a nice idea, but how will anyone know that all the data have been released and that none remain concealed or destroyed?" writes Emily Willingham. Analysis of trial data and design by independent experts would go further in reducing the risk of bias and increasing public confidence, she suggests. Forbes (11/26) LinkedInFacebookTwitterEmail this Story
  From SNMMI 
  • SNMMI's 12 Deals for the Holidays begins today!
    Add an SNMMI online program or book to your holiday wish list. Now through Dec. 21, SNMMI will be heavily discounting a different program or book every other day. It's the perfect opportunity to get the valuable information you need at the savings you love. Visit our holiday deals page for more information! LinkedInFacebookTwitterEmail this Story
  • Have a question?
    Do you have a question about clinical practice or trends, or are you looking for opinions from your colleagues? Join the SNMMI LinkedIn group and pose your question to more than 4,000 nuclear medicine and molecular imaging professionals. Someone may just have an answer for you. LinkedInFacebookTwitterEmail this Story
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

  SmartQuote 
The foolish man seeks happiness in the distance; the wise grows it under his feet."
--James Oppenheim,
American poet, novelist and editor


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
   
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Advertise
Account Director:   Meryl Harold   (202) 407-7828
 
Read more at SmartBrief.com
 
 
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.®  Legal Information